Neurologic complications of immune checkpoint inhibitors

Journal of Neuro-Oncology

Volumn 137, Issue 3, 2018, Pages 601-609

  Fellner, Avi ^a,b   Makranz, Chen ^c   Lotem, Michal ^c   Bokstein, Felix ^b,d   Taliansky, Alisa ^e   Rosenberg, Shai ^c   Blumenthal, Deborah T ^b,d   Mandel, Jacob ^f   Fichman, Suzana ^a,b   Kogan, Elena ^a,b   Steiner, Israel ^a,b   Siegal, Tali ^a   Lossos, Alexander ^c   Yust Katz, Shlomit ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CTLA 4; Immune checkpoint inhibitors; Neurological complications; PD 1

Indexed keywords

ACICLOVIR; AMPICILLIN; C REACTIVE PROTEIN; CEFTRIAXONE; CORTICOSTEROID; CREATINE KINASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNE CHECKPOINT INHIBITOR; IMMUNOMODULATING AGENT; IPILIMUMAB; LIVER ENZYME; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; TROPONIN T; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL ARTICLE; CRANIAL NEUROPATHY; DYSLIPIDEMIA; EYE DISEASE; FEMALE; GLIOBLASTOMA; HODGKIN DISEASE; HUMAN; LOW DRUG DOSE; MALE; MELANOMA; MENINGOENCEPHALITIS; MIDDLE AGED; MORTALITY; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MYASTHENIA; MYOSITIS; NEUROLOGICAL COMPLICATION; NEUROMUSCULAR JUNCTION DISORDER; OCULAR MYASTHENIA; PARANEOPLASTIC NEUROPATHY; POLYRADICULITIS; RASH; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT; FATALITY; NEOPLASM; NEUROLOGIC DISEASE; PATHOLOGY; TIME FACTOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 85041836926     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-018-2752-5     Document Type: Article

References (26)

1. Bellmunt J, Powles T, Vogelzang NJ (2017) A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev 54:58–67
2. Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1–8
3. Sinnadurai M, McDonald KL (2017) Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. J Neurooncol 132:359–372
4. Swaika A, Hammond WA, Joseph RW (2015) Current state of anti-PD-L1 and anti-PD1 agents in cancer therapy. Mol Immunol 67(2 Pt A):4–17
5. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitors. Front Pharmacol 8:49. 10.3389/fphar.2017.00049
6. Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806–812
7. Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J et al (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolmab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22(6):709–718
8. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology 16(4):589–593
9. Nguyen BH, Kuo J, Budiman A, Christie H, Ali S (2017) Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res 27(2):152–154
10. Wick W, Hertenstein A, Platten M (2016) Neurological sequelae of cancer immunotherapies and targeted therapies. Lancet Oncol 17(12):e529–e541
11. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210–225
12. Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP et al (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216–1222
13. Gonzales NL, Puwanant A, Lu A, Marks SM, Zivkovic SA (2017) Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord 27(3):266–268
14. Chang E, Sabichi AL, Sada YH (2017) Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder. J Immunother 40(3):114–116
15. Lau KH, Kumar A, Yang IH, Nowak RJ (2016) Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 54(1):157–161
16. Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T et al (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107(7):1055–1058
17. Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128–136
18. Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127–1134
19. Papadopoulos KP, Romero RS, Gonzales G, Dix JE, Lowy I, Fury M (2017) Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 22:1–3
20. Richard K, Weslow J, Porcella SL, Nanjappa S (2017) A case report of steroid responsive nivolumab-induced encephalitis. Cancer Control 24(5):1–3
21. Brown MP, Hissaria P, Hsieh AH, Kneebone C, Vallat W (2017) Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol 305:16–18
22. Behling J, Kaes J, Munzel T, Grabbe S, Loquai C (2017) New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res 27(2):155–158
23. De Velasco G, Je Y, Bosse D, Awad MM, Ott PA, Moreira RB et al (2017) Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 5(4):312–318
24. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34
25. Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT et al (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73(8):928–933
26. Yshii LM, Gebauer CM, Pignolet B, Maure E, Queriault C, Pierau M et al (2016) CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain 139(11):2923–2934